NCT04376814 is a NA clinical trial of Favipiravir in COVID-19, sponsored by Baqiyatallah Medical Sciences University.

Who is sponsoring NCT04376814?

NCT04376814 is sponsored by Baqiyatallah Medical Sciences University.

What drugs are being tested in NCT04376814?

Interventions in NCT04376814: Favipiravir, Hydroxychloroquine, Lopinavir / Ritonavir.

What condition does NCT04376814 study?

NCT04376814 studies COVID-19, Favipiravir, Kaletra, Hydroxychloroquine, Lopinavir/Ritonavir.

Is NCT04376814 still recruiting?

NCT04376814 is currently completed. Last updated 16 June 2020.

Last reviewed 2020-06-16 · How we verify

NCT04376814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19

Completed NA Last updated 16 June 2020

What this trial tests

NA trial testing Favipiravir in COVID-19 in 40 participants. Completed in 25 May 2020.

Timeline

29 March 2020

Primary endpoint
5 April 2020

25 May 2020

Quick facts

Lead sponsor	Baqiyatallah Medical Sciences University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	29 March 2020
Primary completion	5 April 2020
Estimated completion	25 May 2020
Sites	1 location across Iran

Drugs / interventions tested

Favipiravir (FAVIPIRAVIR) — full drug profile →
Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
Lopinavir / Ritonavir — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →
Favipiravir — all drugs for Favipiravir →
Kaletra — all drugs for Kaletra →
Hydroxychloroquine — all drugs for Hydroxychloroquine →

Sponsor

Baqiyatallah Medical Sciences University

Who can join

Adults 16 to 100, any sex, with COVID-19 or Favipiravir. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, non-randomized clinical trial study. The number of 40 COVID-19 patients with moderate severity will be admitted in progressive care units (PCUs) and intensive care units (ICUs) enrolled in the study. The sampling will be purposive and based on the same independent variables, including age, gender, past medical histories, and the situation of the patient at the admission day, and ventilator support. The patients will be allocated into two groups with different regimens. Group "A" (regimen A)will be defined as Favipiravir 1600 mg a first dose and 600 mg in 3 divided doses daily plus 400 mg in 2 divided doses of Hydroxychloroquine every day. The group "B" (regimen B) will be contained 400 mg of Lopinavir/Ritonavirin 2 divided doses plus the first dose (400 mg) of Hydroxychloroquine. Hydroxychloroquine will not be used for adverse drug reactions. The regimen remained at least 7 up to 10 days. Data will be analyzed using statistical package for social sciences (SPSS) version 18 (SPSS Inc. Chicago, IL, USA) for windows. The variables will be compared using independent and paired T-test for normally distributed variables and Wilcoxon, Chi-square for non-normal distributed variables. The Kaplan Meier test will be used for survival analysis and the one-sample Kolmogorov-Smirnov test for the evaluation of distributions.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2.
Muralidar S, Ambi SV, Sekaran S, Krishnan UM. · · 2020 · cited 184× · PMID 32971147 · DOI 10.1016/j.biochi.2020.09.018
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.
Meini S, Pagotto A, Longo B, Vendramin I, et al · · 2020 · cited 52× · PMID 32629768 · DOI 10.3390/jcm9072050
Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
Sreekanth Reddy O, Lai WF. · · 2021 · cited 39× · PMID 33031623 · DOI 10.1002/cbic.202000595
Novel therapeutic approaches for treatment of COVID-19.
Hossein-Khannazer N, Shokoohian B, Shpichka A, Aghdaei HA, et al · · 2020 · cited 36× · PMID 32494931 · DOI 10.1007/s00109-020-01927-6
COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials.
Chakraborty R, Parvez S. · · 2020 · cited 35× · PMID 32739342 · DOI 10.1016/j.bcp.2020.114184
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Pillaiyar T, Wendt LL, Manickam M, Easwaran M. · · 2021 · cited 32× · PMID 32852058 · DOI 10.1002/med.21724
The Rationale for Potential Pharmacotherapy of COVID-19.
Saber-Ayad M, Saleh MA, Abu-Gharbieh E. · · 2020 · cited 30× · PMID 32423024 · DOI 10.3390/ph13050096
The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.
Das S, Ramachandran AK, Birangal SR, Akbar S, et al · · 2021 · cited 22× · PMID 33846702 · DOI 10.1016/j.medidd.2021.100085

Verify or expand the search:

Other trials of Favipiravir

Trials testing the same drug.

NCT06860334 — UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF · Phase 2 · not yet recruiting
NCT06488300 — Assessing Antiviral Treatments in Early Symptomatic RSV · Phase 2 · recruiting
NCT05940545 — UMIT-1 Trial Favipiravir & Ribavirin for the Treatment of CCHF · Phase 1, PHASE2 · unknown
NCT05648448 — A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza · Phase 2 · recruiting
NCT05502081 — Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hos · Phase 4 · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Baqiyatallah Medical Sciences University trials

Trials by the same sponsor.

NCT06369688 — IDEAL SKIIN CARES Bundle to Prevent Pressure Injury · NA · not yet recruiting
NCT04463420 — Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 · NA · unknown
NCT04466280 — Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVI · NA · withdrawn
NCT04460092 — Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose · NA · unknown
NCT04134403 — Steroids, Thiamine and Ascorbic Acid in Septic Shock · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04376814 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baqiyatallah Medical Sciences University
Last refreshed: 16 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04376814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing